Inside Aqilion’s NLSDays Journey with CEO Sarah Fredriksson
By Greatland
At Nordic Life Science Days , we spoke with Sarah Fredriksson , CEO of Aqilion , a Swedish biotech advancing novel therapies for chronic inflammatory diseases. Sarah shares key updates on Aqilion’s clinical progress, including new data paving the way for Phase 2 trials across the US, Canada, and Europe, and reflects on the value of NLSDays for connecting with investors and partners.
At Nordic Life Science Days, we had the chance to speak with Sarah Fredriksson, CEO of Aqilion, a Swedish biotech company pioneering therapies for chronic inflammatory diseases. Built on deep immunology expertise, Aqilion is advancing a promising pipeline designed to address significant unmet medical needs.
In the interview, Sarah shares exciting updates on new data that mark a key milestone, paving the way for Phase 2 clinical trials across the US, Canada, and Europe. She also reflects on the value of joining NLSDays to connect with investors, secure funding for Phase 2a of AQ280, and meet potential CRO and CDMO partners.
Watch the full interview to hear more about Aqilion’s upcoming milestones and their mission to improve the lives of patients with inflammatory diseases.
Follow Aqilion on LinkedIn to stay updated on their journey.